Deloxi 20 mg (Capsule (Delayed Release))
Medicine Details
Category | Details |
---|---|
Generic | Duloxetine hydrochloride |
Company | Eskayef pharmaceuticals ltd |
Also available as |
Indications
- Major Depressive Disorder (MDD)
- Generalized Anxiety Disorder (GAD)
- Diabetic Peripheral Neuropathic Pain (DPNP)
- Fibromyalgia
- Chronic Musculoskeletal Pain
Pharmacology
Selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Less potent inhibitor of dopamine reuptake. No significant affinity for various receptors. Does not inhibit monoamine oxidase (MAO). Well absorbed. Elimination mainly through hepatic metabolism.
Dosage & Administration
- Specific starting, target, and maximum doses for different conditions
- Benefit from starting at 30 mg once daily
- Gradual dose reduction recommended to avoid discontinuation symptoms
Interaction
Metabolism by CYP1A2 and CYP2D6 isozymes. Co-administration with inhibitors of these isozymes can affect concentration of the product. Examples of drugs inhibiting CYP1A2 metabolism: fluvoxamine, cimetidine, quinolone antimicrobials. Concomitant use with potent inhibitors of CYP2D6 may result in higher concentrations.
Contraindications
- Known hypersensitivity to the drug or inactive ingredients
- Not approved for use in treating bipolar depression
- Not recommended in patients with substantial alcohol use or evidence of chronic liver disease
- Use with caution in patients with controlled narrow-angle glaucoma
Side Effects
- Nausea
- Dizziness
- Dry mouth
- Constipation
- Decreased appetite
- Fatigue
- Somnolence
- Increased sweating
- Hyperhidrosis
- Asthenia
- Slight increase in blood pressure
- No clinically significant differences observed for QT, PR, and QRS intervals between treated and placebo groups
Pregnancy & Lactation
- Pregnancy: Category C
- Labor and Delivery: Effect on labor and delivery in humans is unknown
- Lactation: Unknown excretion into human milk, nursing not recommended
Precautions & Warnings
- Monitor patients for clinical worsening, suicidality, and unusual changes in behavior
- Measure blood pressure prior to initiating treatment and periodically throughout treatment
- Caution about risk of bleeding with concomitant use of the product and certain drugs
- Use cautiously in patients with a history of mania or seizure disorder
Use in Special Populations
Safety and efficacy in pediatric patients have not been established
Overdose Effects
Limited clinical experience with overdose. No specific antidote. General measures employed in overdose management for any drug. Monitoring of airway, oxygenation, ventilation, cardiac rhythm, and vital signs. Gastric lavage and activated charcoal may be indicated
Therapeutic Class
Serotonin-norepinephrine reuptake inhibitor (SNRI)
Storage Conditions
Do not store above 30°C. Keep away from light and out of the reach of children
Related Brands
- Stresin 30 mg (Capsule (Delayed Release)) - unimed-unihealth-pharmaceuticals-ltd
- Loxetine 30 mg (Tablet (Delayed Release)) - aci-limited
- Loxetine 20 mg (Tablet (Delayed Release)) - aci-limited
- Xinolax DR 60 mg (Capsule (Delayed Release)) - opsonin-pharma-ltd
- Xinolax DR 30 mg (Capsule (Delayed Release)) - opsonin-pharma-ltd